Triple win of trial results and bumper fundraise for Janux

28 February 2024

San Diego, USA-based Janux Therapeutics (Nasdaq: JANX) has seen its share price triple after positive early data were announced for JANX007 and JANX008.

The company is developing a broad pipeline of novel immunotherapies using its TRACTr and TRACIr platforms, with candidates from both performing well in Phase Ia trials.

Emerging JANX007 data show what the firm believes could be a best-in-class profile, with promising efficacy and safety data in certain heavily pretreated people with late-stage prostate cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK